Maryam Bidram, Yue Zhao, Natalia G. Shebardina, Alexey V. Baldin, Alexandr V. Bazhin, Mohamad Reza Ganjalikhany, Andrey A. Zamyatnin, Jr., Mazdak Ganjalikhani-hakemi
5 min
Melanoma is an aggressive skin cancer characterized by a high tumor mutation burden (TMB), making it a prime candidate for immunotherapy. While traditional treatments like chemotherapy often lack specificity and cause significant side effects, mRNA-based vaccines offer a modern, precise alternative. These vaccines function by delivering genetic instructions to the patient's cells, prompting them to produce specific tumor antigens that train the immune system to recognize and eliminate malignant cells.
mRNA vaccines are favored for their safety profile, as they do not integrate into the host genome and can be manufactured rapidly at a low cost. However, naked mRNA is inherently unstable and susceptible to degradation by RNases. To address this, researchers employ various stabilization techniques, including chemical modifications (e.g., replacing uridine with N1-methyl-pseudouridine), sequence optimization (codon optimization), and the use of delivery vehicles like lipid nanoparticles (LNPs) or dendritic cells (DCs). These strategies protect the mRNA cargo and facilitate its entry into the cytoplasm, where it can be translated into the target antigen.
Clinical trials have explored two primary approaches: targeting shared tumor-associated antigens (TAAs) or personalized neoantigens specific to an individual patient's tumor mutations. While TAA-based vaccines have shown promise, they are sometimes limited by central tolerance. Neoantigen-based vaccines, which are unique to the patient, often elicit more robust immune responses. A significant trend in current research is the combination of these vaccines with immune checkpoint inhibitors (such as anti-PD-1 or anti-CTLA-4 antibodies). This synergistic approach aims to both prime the immune system with the vaccine and remove the 'brakes' that tumors use to suppress the resulting T-cell response.
Malignant melanoma is one of the most aggressive forms of cancer and the leading cause of death from skin tumors. Given the increased incidence of melanoma diagnoses in recent years, it is essential to develop effective treatments to control this disease. In this regard, the use of cancer vaccines to enhance cell-mediated immunity is considered to be one of the most modern immunotherapy options for cancer treatment. The most recent cancer vaccine options are mRNA vaccines, with a focus on their usage as modern treatments. Advantages of mRNA cancer vaccines include their rapid production and low manufacturing costs. mRNA-based vaccines are also able to induce both humoral and cellular immune responses. In addition to the many advantages of mRNA vaccines for the treatment of cancer, their use is associated with a number of challenges. For this reason, before mRNA vaccines can be used for the treatment of cancer, comprehensive information about them is required and a large number of trials need to be conducted. Here, we reviewed the general features of mRNA vaccines, including their basis, stabilization, and delivery methods. We also covered clinical trials involving the use of mRNA vaccines in melanoma cancer and the challenges involved with this type of treatment. This review also emphasized the combination of treatment with mRNA vaccines with the use of immune-checkpoint blockers to enhance cell-mediated immunity.
Alex: And once you've generated those T-cell clones, the tumor microenvironment becomes the next obstacle.
Sam: That's where combination therapy enters the picture, and it has the clearest clinical rationale. The vaccine generates new, tumor-specific T-cell clones — that's the priming arm. But solid tumors, including melanoma, actively suppress the local immune environment through PD-L1 expression and regulatory T-cell recruitment. Checkpoint inhibitors remove those suppressive signals. So the logic is straightforward: the vaccine tells the immune system what to look for, and the checkpoint inhibitor ensures those T-cells can actually function once they reach the tumor. Recognition and execution — two distinct steps, two distinct interventions.
Alex: What does the clinical evidence actually look like at this point?
Sam: The load-bearing result is the mRNA-4157 trial, combining the personalized vaccine with pembrolizumab in resected high-risk melanoma. It showed a meaningful reduction in recurrence or death compared to pembrolizumab alone. That's a genuinely encouraging signal, but it comes from a relatively small trial, and the field is still waiting on larger confirmatory data. So it supports the mechanistic framing without yet settling the efficacy question at scale.
Alex: What are the constraints that most limit confidence in the current evidence?
Sam: A few things worth flagging. The neoantigen selection pipeline — going from tumor sequencing to a ranked list of peptides likely to be immunogenic — is still imperfect. Predicted MHC binding affinity doesn't always translate to actual T-cell activation, and the algorithms are trained on datasets that may not generalize uniformly across patients. Then there's the manufacturing timeline: synthesizing a patient-specific vaccine within a clinically useful window after surgery is operationally demanding, and that constraint shapes who can actually access the therapy.
Alex: And there's the tumor heterogeneity problem underneath all of this.
Sam: Which is probably the deepest one. If the neoantigens you target are expressed in only a fraction of tumor cells, you're selecting for outgrowth of antigen-negative clones. The escape mechanism is baked into the biology — you train the immune system against a target, and the tumor can evolve around it. That's part of why the combination approach matters beyond additive efficacy. If checkpoint blockade is broadening the immune response while the vaccine is sharpening it, you're potentially covering more of the mutational landscape. Whether that translates to durable responses at scale is the open question the field is working through.
Alex: So this sits somewhere between proof-of-concept and established therapy — mechanistically coherent, early clinical support, but with real outstanding questions around selection, manufacturing, and escape.
Sam: That's a fair characterization. The immunology is relatively well understood at this point. The bottlenecks are computational — better neoantigen prioritization — and manufacturing — faster, more scalable synthesis pipelines. Those are probably where the next meaningful advances come from.
Alex: Thanks for walking through it.
Sam: Thanks for having me.
Alex: Thanks for listening to ResearchPod.